292 related articles for article (PubMed ID: 16795963)
1. Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study.
Singer MV; Schmausser H; Schönfeld G
Hepatogastroenterology; 2006; 53(69):317-21. PubMed ID: 16795963
[TBL] [Abstract][Full Text] [Related]
2. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
3. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Segars LW; Gales BJ
Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
Mantzaris GJ; Sfakianakis M; Archavlis E; Petraki K; Christidou A; Karagiannidis A; Triadaphyllou G
Am J Gastroenterol; 2004 Jun; 99(6):1122-8. PubMed ID: 15180735
[TBL] [Abstract][Full Text] [Related]
5. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
6. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.
Kruis W; Judmaier G; Kayasseh L; Stolte M; Theuer D; Scheurlen C; Hentschel E; Kratochvil P
Eur J Gastroenterol Hepatol; 1995 May; 7(5):391-6. PubMed ID: 7614099
[TBL] [Abstract][Full Text] [Related]
7. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.
Nilsson A; Danielsson A; Löfberg R; Benno P; Bergman L; Fausa O; Florholmen J; Karvonen AL; Kildebo S; Kollberg B
Am J Gastroenterol; 1995 Mar; 90(3):381-7. PubMed ID: 7872274
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
d'Albasio G; Pacini F; Camarri E; Messori A; Trallori G; Bonanomi AG; Bardazzi G; Milla M; Ferrero S; Biagini M; Quaranta S; Amorosi A
Am J Gastroenterol; 1997 Jul; 92(7):1143-7. PubMed ID: 9219787
[TBL] [Abstract][Full Text] [Related]
9. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis.
Zinberg J; Molinas S; Das KM
Am J Gastroenterol; 1990 May; 85(5):562-6. PubMed ID: 2337059
[TBL] [Abstract][Full Text] [Related]
10. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
[TBL] [Abstract][Full Text] [Related]
11. Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis.
Bardazzi G; d'Albasio G; Bonanomi AG; Trallori G; Messori A; Amorosi A; Bartoletti L; Morettini A; Pacini F
Ital J Gastroenterol; 1994 Sep; 26(7):334-7. PubMed ID: 7812025
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.
Mantzaris GJ; Archavlis E; Christoforidis P; Kourtessas D; Amberiadis P; Florakis N; Petraki K; Spiliadi C; Triantafyllou G
Am J Gastroenterol; 1997 Mar; 92(3):454-6. PubMed ID: 9068468
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
14. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.
Rijk MC; van Lier HJ; van Tongeren JH
Am J Gastroenterol; 1992 Apr; 87(4):438-42. PubMed ID: 1348159
[TBL] [Abstract][Full Text] [Related]
15. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
Karamanolis DG; Papatheodoridis GV; Xourgias V
Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1083-8. PubMed ID: 8944370
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of clinical patterns in ulcerative colitis: a long-term follow-up.
Bresci G; Parisi G; Gambardella L; Banti S; Bertoni M; Rindi G; Capria A
Int J Clin Pharmacol Res; 1997; 17(1):17-22. PubMed ID: 9403349
[TBL] [Abstract][Full Text] [Related]
18. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
20. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
